Hangzhou Innogate Pharma Co. Ltd. and Innorace Biopharma Co. Ltd. have patented 20-hydroxyeicosatetraenoic acid (20-HETE) production inhibitors. They are reported to be useful for the treatment of cancer, obesity, diabetes, Alzheimer’s and Parkinson’s disease, osteoporosis, cardiovascular and cerebrovascular disorders, among others.